Farah Zia

1.0k total citations
26 papers, 866 citations indexed

About

Farah Zia is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Oncology. According to data from OpenAlex, Farah Zia has authored 26 papers receiving a total of 866 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 11 papers in Cellular and Molecular Neuroscience and 8 papers in Oncology. Recurrent topics in Farah Zia's work include Neuropeptides and Animal Physiology (10 papers), Receptor Mechanisms and Signaling (7 papers) and Chemical Synthesis and Analysis (4 papers). Farah Zia is often cited by papers focused on Neuropeptides and Animal Physiology (10 papers), Receptor Mechanisms and Signaling (7 papers) and Chemical Synthesis and Analysis (4 papers). Farah Zia collaborates with scholars based in United States, Israel and Hong Kong. Farah Zia's co-authors include Terry W. Moody, Terry W. Moody, Mirela O. Fágárásan, Muriel Draoui, Oluwadamilola Olaku, Illana Gozes, Mati Fridkin, Douglas E. Brenneman, Ariane Davidson and Allan L. Goldstein and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Clinical Cancer Research.

In The Last Decade

Farah Zia

26 papers receiving 844 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Farah Zia United States 19 372 372 242 108 82 26 866
Franco Paolorossi Italy 17 222 0.6× 56 0.2× 269 1.1× 40 0.4× 29 0.4× 41 1.1k
Ya‐Ting Hsu Taiwan 14 255 0.7× 159 0.4× 156 0.6× 54 0.5× 25 0.3× 53 768
Fabio Malugani Italy 17 286 0.8× 58 0.2× 227 0.9× 23 0.2× 26 0.3× 28 941
B. Schmitt Germany 15 216 0.6× 65 0.2× 105 0.4× 22 0.2× 19 0.2× 34 699
Slobodan Milovanović Serbia 14 169 0.5× 140 0.4× 136 0.6× 10 0.1× 59 0.7× 29 531
Lida Kimmel United States 8 474 1.3× 80 0.2× 227 0.9× 14 0.1× 140 1.7× 10 1.3k
John N.D. Wurpel United States 19 491 1.3× 364 1.0× 331 1.4× 13 0.1× 8 0.1× 51 1.2k
Véronique Dorval Canada 16 705 1.9× 179 0.5× 71 0.3× 12 0.1× 93 1.1× 26 1.2k
Rachel Beeri Israel 14 386 1.0× 123 0.3× 65 0.3× 40 0.4× 40 0.5× 29 894
Joanne Wang United States 17 264 0.7× 143 0.4× 288 1.2× 15 0.1× 8 0.1× 27 875

Countries citing papers authored by Farah Zia

Since Specialization
Citations

This map shows the geographic impact of Farah Zia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Farah Zia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Farah Zia more than expected).

Fields of papers citing papers by Farah Zia

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Farah Zia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Farah Zia. The network helps show where Farah Zia may publish in the future.

Co-authorship network of co-authors of Farah Zia

This figure shows the co-authorship network connecting the top 25 collaborators of Farah Zia. A scholar is included among the top collaborators of Farah Zia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Farah Zia. Farah Zia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zia, Farah, Michael H. Baumann, Robert H. Dworkin, et al.. (2023). Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs. Neuropharmacology. 233. 109528–109528. 18 indexed citations
2.
3.
Henningfield, Jack E., Marion A. Coe, Roland R. Griffiths, et al.. (2022). Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling. Neuropharmacology. 218. 109220–109220. 25 indexed citations
4.
Morelli, Maria Pia, Nicole Houston, Stan Lipkowitz, et al.. (2020). Phase I with expansion cohorts in a study of NEO-201 in adults with chemo-resistant solid tumors.. Journal of Clinical Oncology. 38(4_suppl). 129–129. 2 indexed citations
5.
Olaku, Oluwadamilola, et al.. (2015). The Role of Grape Seed Extract in the Treatment of Chemo/Radiotherapy Induced Toxicity: A Systematic Review of Preclinical Studies. Nutrition and Cancer. 67(5). 730–740. 34 indexed citations
6.
Olaku, Oluwadamilola, Farah Zia, Jeans M. Santana, & Jeffrey D. White. (2013). The National Cancer Institute Best Case Series Program. Integrative Cancer Therapies. 12(5). 385–392. 13 indexed citations
7.
Lebowitz, Peter F., Jennifer Eng‐Wong, Sandra M. Swain, et al.. (2004). A Phase II Trial of Neoadjuvant Docetaxel and Capecitabine for Locally Advanced Breast Cancer. Clinical Cancer Research. 10(20). 6764–6769. 30 indexed citations
8.
Purdom, Sally, Sonia B. Jakowlew, Len Neckers, et al.. (2001). Prostaglandin E2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells. Lung Cancer. 31(2-3). 203–212. 54 indexed citations
9.
Moody, Terry W., Julius Leyton, Farah Zia, et al.. (2000). Thymosinα1 is chemopreventive for lung adenoma formation in A/J mice. Cancer Letters. 155(2). 121–127. 18 indexed citations
10.
Moody, Terry W., et al.. (2000). VPAC1Receptors and Lung Cancer. Annals of the New York Academy of Sciences. 921(1). 26–32. 25 indexed citations
11.
Leyton, Julius, Yehoshua Gozes, Joseph R. Pisegna, et al.. (1999). PACAP (6–38) is a PACAP receptor antagonist for breast cancer cells. Breast Cancer Research and Treatment. 56(2). 175–184. 31 indexed citations
12.
Draoui, Muriel, Toyoaki Hida, Sonia B. Jakowlew, et al.. (1996). PACAP stimulates c-fos mRNAs in small cell lung cancer cells. Life Sciences. 59(4). 307–313. 20 indexed citations
13.
Zia, Farah, et al.. (1996). Monoclonal antibody αIR-3 inhibits non-small cell lung cancer growth in vitro and in vivo. Journal of Cellular Biochemistry. 63(S24). 269–275. 42 indexed citations
14.
Moody, Terry W., Farah Zia, Rajesh Venugopal, et al.. (1996). GRP receptors are present in non small cell lung cancer cells. Journal of Cellular Biochemistry. 63(S24). 247–256. 33 indexed citations
15.
Moody, Terry W., et al.. (1995). Neuromedin B stimulates arachidonic acid release, c-fos gene expression, and the growth of C6 glioma cells. Peptides. 16(6). 1133–1140. 23 indexed citations
16.
Moody, Terry W., Rajesh Venugopal, Farah Zia, et al.. (1995). BW2258U89: A GRP receptor antagonist which inhibits small cell lung cancer growth. Life Sciences. 56(7). 521–529. 24 indexed citations
17.
Zia, Farah, et al.. (1995). Pituitary adenylate cyclase activating peptide receptors regulate the growth of non-small cell lung cancer cells.. PubMed. 55(21). 4886–91. 58 indexed citations
18.
Moody, Terry W., Farah Zia, Rajesh Venugopal, et al.. (1994). Corticotropin-releasing factor stimulates cyclic AMP, arachidonic acid release, and growth of lung cancer cells. Peptides. 15(2). 281–285. 12 indexed citations
19.
Moody, Terry W., Farah Zia, & A.N. Makheja. (1993). Pituitary adenylate cyclase activating polypeptide receptors are present on small cell lung cancer cells. Peptides. 14(2). 241–246. 36 indexed citations
20.
Moody, Terry W., Julie K. Staley, Farah Zia, D. H. Coy, & R. T. Jensen. (1992). Neuromedin B binds with high affinity, elevates cytosolic calcium and stimulates the growth of small-cell lung cancer cell lines.. Journal of Pharmacology and Experimental Therapeutics. 263(1). 311–317. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Franco Paolorossi Breakdown of academic impact, for papers by Ya‐Ting Hsu Breakdown of academic impact, for papers by Fabio Malugani Breakdown of academic impact, for papers by B. Schmitt Breakdown of academic impact, for papers by Slobodan Milovanović Breakdown of academic impact, for papers by Lida Kimmel Breakdown of academic impact, for papers by John N.D. Wurpel Breakdown of academic impact, for papers by Véronique Dorval Breakdown of academic impact, for papers by Rachel Beeri Breakdown of academic impact, for papers by Joanne Wang
Rankless by CCL
2026